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Background. Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular
disease (CVD). Maintaining good glycemic control may reduce long-term CVD risk. However, other risk factors such as elevated
vascular sympathetic tone and/or endothelial dysfunction may be stronger potentiators of CVD. This study evaluated the impact
of bromocriptine-QR, a sympatholytic dopamine D2 receptor agonist, on progression of metabolic disease and CVD in T2DM
subjects in good glycemic control (HbA1c ≤7.0%). Methods. 1834 subjects (1219 bromocriptine-QR; 615 placebo) with baseline
HbA1c ≤7.0% derived from the Cycloset Safety Trial (this trial is registered with ClinicalTrials.gov Identifier: NCT00377676), a
12-month, randomized, multicenter, placebo-controlled, double-blind study in T2DM, were evaluated. Treatment impact upon
a prespecified composite CVD endpoint (first myocardial infarction, stroke, coronary revascularization, or hospitalization for
angina/congestive heart failure) and the odds of losing glycemic control (HbA1c >7.0% after 52 weeks of therapy) were determined.
Results. Bromocriptine-QR reduced the CVD endpoint by 48% (intention-to-treat; HR: 0.52 [0.28−0.98]) and 52% (on-treatment
analysis; HR: 0.48 [0.24−0.95]). Bromocriptine-QR also reduced the odds of both losing glycemic control (OR: 0.63 (0.47−0.85),
𝑝 = 0.002) and requiring treatment intensification to maintain HbA1c ≤7.0% (OR: 0.46 (0.31−0.69), 𝑝 = 0.0002). Conclusions.
Bromocriptine-QR therapy slowed the progression of CVD and metabolic disease in T2DM subjects in good glycemic control.
1. Introduction
Cardiovascular disease (CVD) is the leading cause of death
among patients with type 2 diabetes mellitus (T2DM) even
with earlier detection and treatment of T2DMas has occurred
during the past decade. This patient population has a 2-
to 3-fold higher risk of CVD relative to their nondiabetic
counterparts [1]. Yet, the relationship between plasma glucose
concentration and CVD in T2DM remains poorly under-
stood.
Several in vitro and in vivo studies have documented
that hyperglycemia alters cellular biochemistry within the
vasculature, ultimately inducing endothelial dysfunction and
abnormalities in vascular structure and biology predisposing
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T2DM patients to CVD (reviewed in [2]). Nonetheless,
large randomized clinical studies evaluating the impact of
improving glycemic control on CVD outcomes [3–6] failed
to demonstrate an effect of improvement in existing hyper-
glycemia from HbA1c levels >7.0 to ≤7.0 to reduce CVD
outcomes over the duration of the trials. However, posttrial
follow-up andpost hoc analyses of someof these trials suggest
that early reductions in HbA1c may be coupled to modest
long-term improvements in CVD outcomes [7, 8]. In addi-
tion, epidemiological studies indicate that the risks of vascu-
lar complications are strongly associated with glycemic expo-
sure, such that the CVD event rate increases over time as the
mean HbA1c increases above 7.0% prior to the first event [9–
14]. In aggregate, these studies suggest that the effect of reduc-
ing existing hyperglycemia to reduce CVD event rate may
require a long time to be expressed and is of moderate impact
[15]. Apparently, progression of T2DM,with itsmultifactorial
pathological components of the insulin resistance syndrome,
including loss of glycemic control, predisposes to increased
incidence of CVD that cannot then be easily, quickly, and
largely reversed by merely reversing the hyperglycemia.
Moreover, even in T2DM subjects with good glycemic con-
trol, increased risk of CVD is evident. Clearly, more effective
approaches outside of managing dysglycemia are required to
ameliorate these macrovascular complications of T2DM. In
this regard, several lines of evidence suggest that other mech-
anisms such as increased vascular sympathetic tone and/or
endothelial dysfunction may be strong potentiators of CVD
in insulin resistant states [16–21]. Elevated sympathetic tone
contributes significantly to hypertension, cardiac autonomic
neuropathy, insulin resistance, dyslipidemia, vascular reac-
tive oxygen species generation, inflammation, and endothe-
lial dysfunction that each in turn contributes to CVD [16–21].
A current unmet goal of clinical research and prac-
tice in T2DM is the identification of safe and effective
therapies that maintain good glycemic control, preventing
progression of disease, while also reducing the long-term
CVD risk, independent of their impact upon glycemic
control. Bromocriptine-QR, a quick release formulation of
bromocriptine, a sympatholytic dopamine D2 receptor ago-
nist [22, 23] (approved by the U.S. Food and Drug Adminis-
tration for the treatment of hyperglycemia in patients with
T2DM in 2009) may offer a therapy with the potential to
maintain glycemic control and reduce CVD risk [24–28].
Once daily, morning administration of bromocriptine-QR
has been shown to improve glycemic control when used as
either monotherapy or add-on therapy (0.5 to 0.9 HbA1c
reduction relative to placebo control) in T2DM subjects with
poor glycemic control (HbA1c ≥ 7.5) [27, 28]. In addition, in
a large T2DM study population (Cycloset Safety Trial (CST);
𝑁 = 3070) comprised of subjects across a wide range of
glycemic control status (A1c range: 5.5–10.5; median [25th–
75th percentile]: 6.8 [6.2–7.6]) whose hyperlipidemia and
hypertension were well controlled and yet with preexisting
CVD history (33% of population), intervention with this
agent resulted in a 40%hazard risk reduction of a prespecified
composite CVD endpoint over a period of one year [24].
Available evidence suggests that bromocriptine-QR may
work through restoration of the dailymorning peak in central
circadian dopaminergic neural activities [29–32] to reduce
themajorCVD risk factors of hyperactive sympathetic tone at
the vasculature, endothelial dysfunction, and vascular oxida-
tive and nitrosative free radical generation [33, 34], each inde-
pendently of any effect on fasting plasma glucose or lipid lev-
els. These neuroendocrine aberrations are operative in pro-
gression of CVD over the entire continuum of glycemic con-
trol in T2DM patients, including those with good glycemic
control, as they are also present in the prediabetic state
[35–38]. Therefore, we hypothesized (1) that even in T2DM
subjects with good glycemic (and lipid and blood pressure)
control with standard of care, the CVD event rate may still
be high due to the presence of these underlying etiological
neuroendocrine pathologies and (2) that such subjects would
benefit from administration of bromocriptine-QR to produce
a potent and rapid reduction in CVD event rate via its ben-
eficial effects on the above neuroendocrine pathologies, irre-
spective of such existing good glycemic (lipid and blood pres-
sure) control. However, the antidiabetes and CVD protective
effects of bromocriptine-QR in this specific cohort of T2DM
subjects withwell-controlled glycemia have never been inves-
tigated. Hence, to test this hypothesis, we analyzed the data
from the Cycloset Safety Trial (CST) [24], which had enrolled
subjects across a wide spectrum of glycemic control status
ranging from very good to very poor control and afforded the
unique opportunity to investigate, for the first time, the effects
of bromocriptine-QR on progression of both dysglycemia
and CVD in a relatively large population of subjects with
well-controlled T2DM (HbA1c ≤ 7.0; median [25th–75th per-
centile]: 6.4 [6–6.7] in contradistinction to CST subjects with
HbA1c >7.0; median [25th–75th percentile]: 7.8 [7.4–8.5]).
2. Methods
2.1. Study Subjects and Design. The current study population
was derived from those subjects within the CST [24] with
a baseline HbA1c ≤7.0. Of the 3070 subjects randomized
2 : 1 to treatment with bromocriptine-QR versus placebo in
CST, 1834 subjects (1219 receiving bromocriptine-QR and 615
receiving placebo) had baseline HbA1c ≤7.0.The study proto-
col and design for the CST have been previously described
[24]. Briefly, this was a 12-month, multicenter, placebo-
controlled, double-blind, parallel-group safety and efficacy
study in outpatient T2DM subjects recruited from general
practice and diabetes clinics across 74 clinical centers in the
United States andPuertoRico. Subjectswere between the ages
of 30 and 80 years and had a body mass index <43 kg/m2 and
an HbA1c ≤10.0%. Subjects with New York Heart Classifica-
tions I and II congestive heart failure (CHF) were allowed
to participate, as were subjects with a history of myocardial
infarction (MI) or coronary revascularization occurring >6
months before enrollment. Subjects were required to have
maintained a stable diabetes treatment regimen for ≥30
days prior to randomization, consisting of either lifestyle
interventions of medical nutrition therapy and appropriately
prescribed physical activity, oral antihyperglycemic agents
(≤2), or insulin either alone or in combination with 1 oral
antihyperglycemic agent.
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The study drug was titrated by adding 1 tablet (0.8mg
bromocriptine-QR per tablet) per week until a maximum tol-
erated daily dose between 2 and 6 tablets (1.6 to 4.8mg/day)
was achieved. The study drug was taken once daily with
the morning meal, within 2 hours of waking. Subjects were
required to continue their established antihyperglycemic
treatments during the first 3 months of the study. However,
the dosages of the oral agents or insulin could be modified
as deemed appropriate by the study site investigator. After 3
months, alterations in the diabetes treatment regimen were
allowed, if deemed necessary by the study site investigator, as
long as these changes did not result in a final regimen that
exceeded 2 oral agents or insulin plus 1 oral agent, exclusive
of the study drug.
The study protocol was approved by site-specific or
central institutional review boards and all subjects provided
written informed consent to participate in the study before
enrollment. This current study and analyses are original
and different from any previously reported results from the
Cycloset Safety Trial.
2.2. Study Endpoints and Statistical Analyses
2.2.1. Two Primary Endpoints Were Evaluated in This Study
CVD Endpoint. The same prespecified CVD endpoint of the
CST (a composite of major cardiovascular events, defined as
a composite of first MI, stroke, coronary revascularization,
or hospitalization for angina or CHF that occurred after ran-
domization) was also used in this new study and analysis. An
independent event adjudication committee consisting of two
cardiologists and an endocrinologist, blinded to treatment
assignment andMedical Dictionary for Regulatory Activities
coding of events by the study team, made the final serious
adverse event (SAE) system organ class (SOC) classifications
and assignment of an SAE as a CVD endpoint. Statistical
analyses were performed using Cox proportional-hazards
regression. Intention-to-treat (ITT) and on-treatment (OT)
analyses were conducted. ITT analysis included all patients
receiving at least one dose of the study drug with expo-
sure time being one year or time to event. To account
for any possible influence of weighted early termination
among bromocriptine-QR versus placebo treated subjects
that might artificially impact the ITT analysis, an OT anal-
ysis restricting exposure time to time on study drug was
also conducted. Superiority between bromocriptine-QR and
placebo for the CVD endpoint was defined as the upper
bound of the two-sided 95% confidence limit being <1.0 and
the superiority analysis of CVD endpoint was based on the
Cox proportional-hazards regression, adjusted for baseline
covariates including history of stroke, revascularization, and
center, with two-sided 𝑝 values calculated. The cumulative
incidence rate of the CVD endpoint was analyzed by log-
rank test. A Kaplan-Meier curve for events over time was
generated. The significance level was set at 𝑝 < 0.05.
Glycemic Control Endpoint.The impact of bromocriptine-QR
versus placebo on the progression of diabetes was described
as the odds of losing glycemic control while on therapy and
determined by evaluating the percent of subjects completing
52 weeks of therapy, whose HbA1c progressed above 7.0%.
The odds of requiring treatment intensification to maintain
HbA1c ≤7.0% during the study period of 52 weeks were also
analyzed. To eliminate potential confounding arising from
intensification of concomitant antidiabetes medications, the
analyses were also performed in only those subjects complet-
ing 52 weeks without requiring any concomitant antidiabetes
treatment intensification. The above analytical approach was
also conducted on the entire study population using a last
observation carry-forward analysis.
Statistical analyses of the primary endpoints and safety
measures were conducted independently by Everest Inc.
(Ontario, Canada) using SAS software version 8.2 (Cary,NC).
Safety analyses were conducted as previously described
for the CST [24].
3. Results
3.1. Baseline Characteristics of Study Subjects. There were
no significant differences in baseline demographics between
the bromocriptine-QR and placebo study arms although the
HbA1c level was not considered as a stratification factor in
the CST (Table 1(a)). The study population carried multiple
risk factors for CVD and was comprised of individuals
among whom 74% were hypertensive, 75% were hyperlipi-
demic, greater than 50% were prior or current smokers,
approximately 33% had preexisting CVD who were obese on
population average with an average BMI of >32 (Table 1(a)).
Fasting plasma glucose, lipids, and blood pressure were well
controlled in both groups. Majority of the subjects were
receiving cardioprotective medications (see Table 1(b) for
details).
3.2. Subject Disposition. 1834 patients (1219 receiving bro-
mocriptine-QR and 615 receiving placebo) from the CST
trial had baseline HbA1c ≤7.0% and were included in this
study. In total, 92% of the planned person-year CV outcome
ascertainment was observed in this trial (1772 of 1920 possible
total person-years), with 77% of bromocriptine-QR subjects
and 83% of placebo subjects providing a week 52 plus 30-day
follow-up outcome assessment. The number of subjects with
HbA1c assessment at Week 52 was 1203 (750 bromocriptine-
QR and 453 placebo). Details of subject disposition and
delineation of person-year CV outcome ascertainment are
shown in Figure 1.
3.3. CVD Endpoint. In the ITT analysis, the composite CVD
endpoint occurred in 19 bromocriptine-QR-treated (1.6%)
and 19 placebo-treated (3.1%) subjects, resulting in a 48%
CVD hazard risk reduction (hazard ratio [HR] 0.52, CI
0.28−0.98) (Table 2). The OT analysis revealed a 52% CVD
risk reduction (HR: 0.48; CI: 0.24−0.95) (Table 2). Figure 2
depicts the Kaplan-Meier curve of the cumulative incidence
rate of the composite CVD endpoint by treatment and
demonstrates a significant difference at 1 year (log rank 𝑝 =
0.041).
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Table 1: (a) Baseline demographics, laboratory, and vital measures of study population. (b) Baseline antihyperglycemic and antihyperten-
sive/cardioprotective medications of study populationa.
(a)
Variable
All patients with incoming HbA1c ≤7.0 Patients with incoming A1c ≤7.0that completed 52 study weeks
Bromocriptine-QR
(𝑁 = 1,219)
Placebo
(𝑁 = 615)
Bromocriptine-QR
(𝑁 = 750)
Placebo
(𝑁 = 453)
Age (years) 60.4 ± 10.1 60.4 ± 10.1 60.9 ± 9.6 60.8 ± 9.9
Duration of diabetes (years) 6.8 ± 6.9 6.6 ± 6.5 6.7 ± 6.5 6.7 ± 6.8
Male sex 673 (55) 335 (54) 454 (61) 262 (58)
Race:
White 869 (71) 431 (70) 546 (73) 327 (72)
Black 183 (15) 110 (18) 113 (15) 76 (17)
Hispanic 142 (12) 63 (10) 74 (10) 41 (9)
Asian 10 (1) 6 (1) 7 (1) 5 (1)
Other 15 (1) 5 (1) 10 (1) 4 (1)
Comorbid conditions
Hypertension 908 (74) 457 (74) 558 (74) 348 (77)
Angina pectoris 119 (10) 57 (9) 79 (11) 45 (10)
Myocardial infarction 98 (8) 52 (8) 62 (8) 44 (10)
Revascularization 111 (9) 69 (11) 69 (9) 57 (13)
Stroke 43 (4) 29 (5) 29 (4) 21 (5)
Hypercholesterolemia∗ 914 (75) 458 (74) 574 (77) 351 (77)
Hypertriglyceridemia∗ 470 (39) 241 (39) 297 (40) 181 (40)
Current smoker 161 (13) 73 (12) 98 (13) 48 (11)
Former smoker 495 (41) 258 (42) 321 (43) 193 (43)
HbA1c (%) 6.3 ± 0.49 6.3 ± 0.48 6.3 ± 0.48 6.3 ± 0.47
Fasting glucose (mmol/L) 7.00 ± 1.56 6.89 ± 1.44 7.06 ± 1.56 6.83 ± 1.44
Total cholesterol (mmol/L) 4.58 ± 1.03 4.53 ± 0.93 4.47 ± 0.96 4.53 ± 0.93
LDL cholesterol (mmol/L) 2.51 ± 0.83 2.48 ± 0.75 2.43 ± 0.78 2.48 ± 0.75
HDL cholesterol (mmol/L) 1.19 ± 0.31 1.22 ± 0.31 1.19 ± 0.31 1.19 ± 0.28
Triglycerides (mmol/L) 1.94 ± 1.33 1.86 ± 1.22 1.93 ± 1.23 1.91 ± 1.32
Systolic BP (mmHg) 130 ± 14 129 ± 13 130 ± 14 129 ± 13
Diastolic BP (mmHg), 77 ± 9 77 ± 9 77 ± 9 76 ± 9
Creatinine (𝜇mol/L) 97.24 ± 17.68 97.24 ± 17.68 97.24 ± 17.68 97.24 ± 17.68
Body mass index (kg/m2) 32.2 ± 5.0 32.3 ± 5.1 32.3 ± 5.0 32.2 ± 5.0
Data are shown as means ± SD for continuous variables and number (%) for categorical variables.
∗Based on history as assessed by study site investigator.
(b)
Variable
All patients with incoming HbA1c ≤7.0 Patients with incoming HbA1c ≤7.0that completed 52 weeks of study
Bromocriptine-QR
(𝑁 = 1,219)
Placebo
(𝑁 = 615)
Bromocriptine-QR
(𝑁 = 750)
Placebo
(𝑁 = 453)
Diabetes Treatment Regimen
Diet only 194 (16) 93 (15) 115 (15) 67 (15)
One oral hypoglycemic agent 570 (47) 304 (49) 365 (49) 221 (49)
Two oral hypoglycemic agents 350 (29) 154 (25) 203 (27) 117 (26)
Oral agent plus insulin 59 (5) 30 (5) 43 (6) 24 (5)
Insulin only 45 (4) 34 (6) 24 (3) 24 (5)
Not reported 1 0 0 0
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(b) Continued.
Variable
All patients with incoming HbA1c ≤7.0 Patients with incoming HbA1c ≤7.0that completed 52 weeks of study
Bromocriptine-QR
(𝑁 = 1,219)
Placebo
(𝑁 = 615)
Bromocriptine-QR
(𝑁 = 750)
Placebo
(𝑁 = 453)
Anti-diabetes Medications by Agent—no. (%)
Insulin 104 (9) 64 (10) 67 (9) 48 (11)
Metformin 698 (57) 347 (56) 412 (55) 262 (58)
Thiazolidinediones 238 (20) 116 (19) 148 (20) 83 (18)
Sulfonylureas 406 (33) 187 (30) 260 (35) 141 (31)
Other 16 (1) 10 (2) 11 (1) 7 (2)
Cardio-protective Medications by Class—no.
(%)
ACE Inhibitors 578 (47) 275 (45) 370 (49) 216 (48)
Angiotensin II Receptor Inhibitors 215 (18) 123 (20) 127 (17) 92 (20)
Beta Blockers 278 (23) 156 (25) 180 (24) 125 (28)
Diuretics 411 (34) 215 (35) 255 (34) 158 (35)
Calcium Channel Blockersb 198 (16) 120 (20) 119 (16) 89 (20)
HMG CoA Reductase Inhibitor 711 (58) 360 (59) 452 (60) 274 (60)
Fibrate 86 (7) 42 (7) 59 (8) 36 (8)
Platelet Aggregation Inhibitors 554 (45) 288 (47) 363 (48) 221 (49)
Cardio-protective Medications by
Number—no. (%)
Taking 1 cardioprotective agent 218 (18) 101 (16) 127 (17) 78 (17)
Taking 2 cardioprotective agents 266 (22) 148 (24) 169 (23) 106 (23)
Taking 3 cardioprotective agents 238 (20) 113 (18) 157 (21) 88 (19)
Taking ≥4 cardioprotective agents 369 (30) 186 (30) 233 (31) 143 (32)
aIncludes fixed dose combinations.
bCalcium channel blockers include dihydropryidine, pheny-alkylamine, benozothiazepine.
Table 2: Impact of bromocriptine-QR on a prespecified, adjudicated composite CVD endpoint, and individual components of the composite.
Bromocriptine-QR
𝑁 = 1219
Placebo
𝑁 = 615 Hazard ratio (95% CI)
# subjects (%)a # subjects (%)a
Intention to treat analysis
Prespecified adjudicated composite CVD endpoint
(ITT) 19 (1.6) 19 (3.1) 0.52 (0.28–0.98)
Composite CVD endpoint by each component
Myocardial infarction 5 (0.4) 5 (0.8) 0.54 (0.16–1.86)
Stroke 1 (0.1) 3 (0.5) 0.18 (0.02–1.71)
Hospitalization for angina 4 (0.3) 3 (0.5) 0.71 (0.16–3.15)
Hospitalization for heart failure 3 (0.2) 4 (0.7) 0.36 (0.08–1.62)
Coronary revascularization 6 (0.5) 4 (0.7) 0.81 (0.23–2.86)
Coronary revascularization following a primary
endpoint (e.g., CABG after MI) 7 (0.6) 7 (1.1) 0.53 (0.19–1.52)
On treatment analysis
Prespecified adjudicated composite CVD endpoint 15 (1.2) 18 (2.9) 0.48 (0.24–0.95)
a% of events per total𝑁 per group (1219 bromocriptine-QR, 615 placebo).
CI: confidence interval, CV: cardiovascular, CABG: coronary artery bypass graft, MI: myocardial infarction.
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4074 assessed for eligibility
1004 ineligible
669 protocol ineligibility 
184 withdrawal of consent
2 administrative
58 lost to follow up 
91 other 
Bromocriptine-QR Placebo
456 stopped treatment prior
to week 52
283 adverse events
15 protocol deviations
99 withdrawal of consent
8 investigator decision 
9 sponsor decision
37 other 
1 no outcome reported
26 (4.2%) lost to 
follow up
1444 subjects completed a final assessment at week 52 or 56 for the study endpoint and 390 terminated prior to week 52 contributing some time on
155 stopped treatment prior
to week 52
69 adverse events 
13 protocol deviations
45 withdrawal of consent
4 investigator decision
2 sponsor decision
21 other 
693
completed
study on 
drug
(747
person-
years)
19 completed
the study
off drug
(19 person-
years)
69 (5.7%) lost to follow up
58 completed
the study
off drug
(59 person-
years)
183 completed
week 52 phone
call
(242 person-
years)
285 terminated the study early
with no added follow up
(includes lost to follow-up)
(116 person-years)
57 completed
week 52
phone call
(67 person-
years)
105 terminated the study early
with no added follow-up
(includes lost to follow-up)
(52 person-years)
434
completed 
study on
drug
(469
person-
years)
935 completed a final assessment at week 52 or 56 for the
study endpoint (1049 person years) (sum of boxes 1, 2, 3)
510 completed a final assessment at week 52 or 56 for the study
endpoint (555 person years) (sum of boxes 5, 6, 7)
2 : 1 bromocriptine-QR to placebo randomization n = 3070
Bromocriptine-QR n = 2054 placebo n = 1016
(n = 1834)
N = 615
Baseline HbA1c ≤ 7.0
n = 1219
4 deaths∗ 1 death∗
1219 bromocriptine-QR and 615 placebo subjects included in the ITT analysis. Total expected person years = 1920: bromocriptine-QR 1272,
Sum of boxes 1, 2, 3, 4 = 1165 person years on bromocriptine-QR. Sum of boxes 5, 6, 7, 8 = 608 person years on placebo
∗Deaths: bromocriptine-QR 4 deaths (all deaths occurred while on treatment and were classified as unlikely related by site investigators);
placebo 1 death (occurred on treatment and relatedness was unclassified by site investigator)
①
placebo 648
study accounting for a total person time of 1772 person years (92% of expected)
② ③ ④
⑤
⑥⑦⑧
Abbreviations: ITT—, intention-to-treat
Figure 1: Disposition of study subjects.
There were no significant changes in plasma lipid levels
or heart rate in either treatment group. Compared to placebo,
the bromocriptine-QR treated group exhibited a mild reduc-
tion in blood pressure (change from baseline blood pressure
(mean ± SD; mmHg): −2.81 ± 16.27 systolic and −1.89 ± 9.76
diastolic in the bromocriptine group; −0.54 ± 14.86 systolic
and −0.56 ± 9.54 diastolic in the placebo group; between
group difference (CI): −1.76 (−3.09, −0.42) systolic (𝑝 =
0.0099) and −1.19 (−2.00, −0.38), (𝑝 = 0.0038) diastolic).
3.4. Glycemic Control Endpoint. Among study subjects whose
HbA1c remained ≤7.0 during the study period, bromocript-
ineQR intervention reduced the fraction of subjects that
required intensified concomitant antidiabetes therapy to do
so by 47%for the completer population and by 58% for the
ITT population (see Table 3 for details).
Analyzing all subjects who had a 52-week HbA1c mea-
surement, irrespective of changes in concomitant diabetes
therapy and adjusting for baseline HbA1c, the odds of losing
glycemic control (HbA1c >7.0% after 52 weeks of treatment)
were significantly lower with bromocriptine-QR therapy (OR
(95% CI): 0.63 (0.47–0.85), 𝑝 = 0.002). The odds of requiring
treatment intensification to maintain HbA1c ≤7.0% over
the course of the study were also significantly lower with
bromocriptine-QR therapy (OR (95% CI): 0.46 (0.31–0.69),
𝑝 = 0.0002). On repeating the analysis including only those
subjects who did not have a change in the intensity of their
concomitant diabetes regimen, bromocriptine-QR was still
associated with significantly lower odds of losing glycemic
control compared with placebo (18% versus 26%, resp.) (OR
(95% CI): 0.56 (0.39–0.80), 𝑝 = 0.002). These differences
between the treatment groups were unaffected and remained
significant (𝑝 = 0.001) after adjusting for body weight
changes during the study. The same results described above
were observed using a last observation carry forward analysis
among all subjects with a screening HbA1c value ≤7.0% (ITT
population, 𝑁 = 1834) (see Table 3 for details). For the
ITT population, the between-group difference in change
Journal of Diabetes Research 7
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13
Month
Cu
m
ul
at
iv
e p
er
ce
nt
 w
ith
 ca
rd
io
va
sc
ul
ar
 S
A
Es
Number of subjects with outcome ascertainment
Bromocriptine-QR
Placebo
1219
615
1085
575
1010
546
915
492
Log rank p = 0.041
HR 0.52 (0.275–0.985)
Standard of diabetes care + placebo
Standard of diabetes care + bromocriptine-QR
Figure 2: Kaplan-Meier estimates of the proportion of subjects by treatment that experienced an event within the composite CVD endpoint.
from baseline HbA1c (6.3 ± 0.5) was −0.17 (CI −0.23, −0.11;
bromocriptine-QR: 0.18, placebo: 0.35; 𝑝 < 0.0001).
3.5. Safety Analyses. Adverse events (AEs) that were most
commonly reported (occurring in greater than 5% of subjects
in either group) are shown in Table 4 and were similar
to those previously reported for the CST. Among the AEs
occurring at a higher rate in the bromocriptine-QR group,
the between-group difference was significant (𝑝 < 0.0001)
for nausea (31.7% versus 8.0%), dizziness (15.5% versus 8.6%),
fatigue (13.9% versus 7%), and vomiting (8.7% versus 3.4%),
with the severity reported as beingmild-moderate in>90%of
all cases in each of these categories.The increased rate of nau-
sea, the most common adverse event reported, was transient
and confined to the initial 6-week drug titration period with
an average weekly rate of approximately 6% and decreasing
to <1% thereafter (see Figure 3). Hypoglycemic episodes
occurred infrequently (5.5% bromocriptine-QR versus 4.2%
placebo) with no significant between-group difference in the
rate. Arthralgiawas reduced by 39% in the bromocriptine-QR
group (𝑝 = 0.03).
In the bromocriptine-QR treated group 105 subjects
(8.6%) reported 149 serious adverse events (SAE) while the
placebo-treated group had 58 subjects (9.4%) reporting 80
serious adverse events. In the cardiac disorders body system
class there were 33 events reported in 28 subjects (2.3%)
in the bromocriptine-QR group and 25 events reported in
21 subjects (3.4%) in the placebo group. No other body
system classes had SAE occurring in greater than 2% of either
group.
There was no between group difference in change
from baseline body weight (bromocriptine-QR: 0.386 versus
placebo: 0.366, 𝑝 = 0.97).
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Figure 3: Occurrence of nausea (most commonly reported adverse
event) by study week.
4. Discussion
The findings of this study demonstrated that, in metaboli-
cally well-controlled T2DM subjects (baselineHbA1c≤7.0%),
adding bromocriptine-QR treatment to their baseline estab-
lished diabetes treatment regimen significantly aided in
maintaining good glycemic control, with a lower likelihood
of progressing above an HbA1c of 7.0% or requiring intensifi-
cation of treatment over the ensuing year to maintain HbA1c
≤7.0%. Furthermore, bromocriptine-QR treatment was also
associated with a 48% CVD event rate reduction within the
1-year study duration in this population of T2DM subjects,
with excellent baseline glycemic control (HbA1c 6.3 ± 0.5).
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Table 4: Most commonly reported (≥5% in either treatment group)
adverse events.
Bromocriptine-QR
𝑁 = 1219
Placebo
𝑁 = 615
𝑁 (%) 𝑁 (%)
Nausea 386 (31.7)∗ 49 (8.0)
Dizziness 189 (15.5)∗ 53 (8.6)
Headache 141 (11.6) 54 (8.8)
Fatigue 170 (13.9)∗ 43 (7.0)
Vomiting 106 (8.7)∗ 21 (3.4)
Constipation 69 (5.7) 31 (5.0)
Hypoglycemia 67 (5.5) 26 (4.2)
Diarrhea 92 (7.5) 49 (8.0)
Nasopharyngitis 64 (5.3) 34 (5.5)
Upper
respiratory
infection
60 (4.9) 40 (6.5)
Arthralgia 47 (3.8)† 38 (6.2)
∗Between-group difference 𝑝 < 0.0001.
†Between-group difference 𝑝 = 0.03.
The study population had multiple cardiometabolic risk
factors for cardiovascular disease at baseline (Table 1(a)) and
the placebo-arm of the study population had a relatively high
event rate (3.1%) for the prespecified serious cardiovascular
adverse event endpoint while being well controlled pharma-
cologically for dysglycemia and on population average for
dyslipidemia and hypertension aswell.These findings suggest
that, in this T2DM subject population demographic, (1) there
are biochemical pathological factors beyond hyperglycemia,
hyperlipidemia, and high blood pressure predisposing this
population to CVD events and (2) there likely are significant
mechanisms beyond glycemic control contributing to the
observed CVD risk reduction with this therapy.
Although epidemiological evidence [9–14] supports an
adverse role of poor glucose control on CVD risk, interven-
tion trials have been less conclusive. Of the earlier studies,
the United Kingdom Prospective Diabetes Study (UKPDS)
demonstrated that intensive glycemic control in individuals
with newly diagnosed T2DM reduced the risk ofmicrovascu-
lar complications [3]. Further, longer-term follow-up of these
individuals for 10 more years after the end of the intervention
trial demonstrated continued reductions in microvascular
disease risk and statistically significant benefits on both
CVD endpoints and total mortality in the intensive therapy
arm, despite the mean HbA1c between the groups having
converged soon after the randomized phase of the trial had
concluded [7]. The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study [4], the Action in Diabetes and
Vascular Disease (ADVANCE) study [5], and the Veterans
Affairs Diabetes Trial (VADT) [6] that were shorter in
duration than UKPDS enrolled older patients, with more
advanced and poorly controlled diabetes, and known CAD
or at high risk for CVD and found no significant decrease
in CVD endpoints with intensive glucose control. However,
the evidence from/post hoc analyses of these large trials [8–
10] and the longer-term UKPDS follow-up [7] suggests long-
lasting benefits of tighter glycemic control in patients that are
younger and earlier in the course of their diabetes or with
lowerHbA1c values (at about 7.0) at treatment intensification.
In these individuals, maintaining HbA1c <7.0% remains a
reasonable target and may have important benefits in reduc-
ing the future burden of macrovascular and microvascular
disease. The bromocriptine-QR effect to slow progression
of dysglycemia in these individuals as demonstrated herein
may therefore offer CVD benefits over the long-term; how-
ever, the rapid response to bromocriptine-QR respecting the
reduction in CVD outcomes observed in the present study
begs for other mechanisms operative in the manifestation
of this effect. Moreover, although bromocriptine has been
shown to reduce hypertriglyceridemia [39] and elevated
blood pressure [23], these effects cannot be responsible for
the observed CVD event rate reduction as these parameters
were well controlled at baseline and minimally affected by
the intervention. Prior studies of the neuroendocrine impact
of timed bromocriptine administration in insulin resistant
animals and humans however may offer insights into a
possible mechanism for the observed CVD (and metabolic)
response to the therapy as follows.
Bromocriptine-QR therapy is a circadian-timed admin-
istration of a quick-release, high absorbing, and short half-
life formulation of bromocriptine. It has been formulated
and administered in the morning within 2 hours of waking
to provide a discrete and brief daily interval of circulating
bromocriptine [24–28, 39], thereby providing a timed pulse
of increased dopaminergic activity centrally at the time of
day that studies suggest is the natural daily peak of central
dopaminergic activity in healthy individuals [32, 40]. Studies
indicate that disturbed circadian rhythmicity of the biological
clock (hypothalamic suprachiasmatic nucleus (SCN)) and a
reduced dopaminergic tone within the central nervous sys-
tem are associatedwith the development of insulin resistance,
obesity, and diabetes [26, 29, 32, 35, 41–47]. A diminution of
the daily circadian peak in dopaminergic activity at the SCN
at the onset of the daily locomotor activity rhythm (e.g., wak-
ing from night-time sleep in humans) is coupled to increases
in hypothalamic ventromedial and paraventricular nuclei
drive for increased sympathetic and hypothalamic-pituitary-
adrenal (HPA) axis activities (reviewed in [35]). These
increased sympathetic/HPA activities potentiate increases in
adipose lipolysis and subsequent plasma free fatty acid levels,
increases in hepatic glucose and lipid output and decreases
in hepatic glucose storage, and increased peripheral insulin
resistance [33, 35], particularly during the postprandial state
[36]. When bromocriptine is administered at the appropriate
time of day to restore normal SCN dopaminergic activ-
ity in insulin resistant states, it normalizes such aberrant
hypothalamic functions and elevated sympathetic tone and
the HPA axis circadian activity [35]. When administered
to humans in the early morning upon waking in an effort
to restore the normal waking rise in central dopaminergic
activity that is diminished in insulin resistant states [32,
35], bromocriptine-QR improves insulin resistance and other
metabolic abnormalities [26–28, 39, 42].
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While the mechanisms by which timed bromocriptine-
QR therapy produces the observed effects on CVD outcomes
are yet to be fully delineated, available evidence suggests
important CVD-protective roles for its modulation of central
nervous system and circadian hypothalamic functions to
reduce elevated sympathetic nervous system (SNS) (and
HPA axis) activities (as described above) that directly and
indirectly potentiate vascular inflammation, endothelial dys-
function, and arterial stiffening [16–18] and that are coupled
to increased CVD risk if overactive [16, 48]. Such SNS
influences on adipose and liver potentiate their increased
secretion of FFA/lipid and inflammatory cytokines that in
turn cause vascular inflammation and reactive oxygen species
generation that are damaging to the vasculature [19–21].
Increases in SNS activities can also induce a proinflammatory
response in various arms of the immune system itself that
can also predispose to vascular damage [49]. Additionally,
and likely much more importantly, increased SNS activity
can produce adverse cardiometabolic effects directly upon
the vasculature to potentiate vasoconstriction, generation
of vascular reactive oxygen and nitrogen species, increased
inflammation, endothelial dysfunction, and arteriosclerosis
[16–18, 50]. Furthermore, changes in vascular inflamma-
tion and endothelial function (positive or negative) can
manifest changes in vascular pathology/physiology quickly
[16–21, 37, 38]. Importantly, circadian timed treatment of
spontaneously hypertensive rats (SHR) with bromocriptine
has demonstrated improvements in metabolic syndrome
parameters including elevated SNS tone, fatty liver, and
hepatic inflammation [33], as well as reductions in arterial
stiffness and endothelial nitric oxide synthase uncoupling
[33], two phenomena commonly observed in patients with
T2DM and strongly linked to progression of macrovascular
disease [19–21]. Others have reported similar hepatic and
vascular findings in response to bromocriptine therapy in
other animal models [51, 52]. Also, beyond normalizing
(resetting) hypothalamic control of elevated sympathetic
tone and vascular dysfunction, bromocriptine has direct
sympatholytic activity due to its neurotransmitter receptor
modulation capacity [22, 23, 53]. Endothelial dysfunction,
vascular inflammation, and elevated sympathetic tone are
early pathological events in the progression of CVD and
precede the onset of T2DM [16–21, 37, 38]. As such, these
pathologies may well have contributed to the 3.1% CVD
event rate observed in this study placebo population that
was well controlled for hyperglycemia, hyperlipidemia, and
high blood pressure with standard of care therapy. That
is to say, such T2DM subjects whose dysglycemia, dyslipi-
demia, and hypertension are well controlled with standard
of care pharmacotherapy still remain in need of therapy for
their underlying substantive CVD risk due to these above
described neuroendocrine pathologies. Therefore, if these
pathologies are the targets of this bromocriptine-QR therapy,
as available evidence suggests, then the present findings
suggest that early intervention with this therapy in the course
of T2DM may potentially provide longer-term benefit of
CVD risk reduction.
The limitations of this study include the relatively small
number of CVD events and the short duration of the trial.
Other limitations include the lack ofmechanistic information
relating to bromocriptine-QR impact on sympathetic tone or
endothelial dysfunction in the study population. Therefore,
caution should be exercised when evaluating these CVD
findings and their full potential clinical ramifications. The
abovementioned mechanisms proposed to be operative in
the observed CVD outcome results of this study need to
be further investigated in human studies (e.g., impact of
bromocriptine-QR on vascular inflammation, endothelial
dysfunction, vascular and systemic reactive oxygen species
status, and aortic compliance) before definitive conclusions
on such mechanisms can be made. It should be appreciated
though that the study subjects had multiple risk factors
for CVD at baseline and the prespecified CVD endpoint
occurred in the placebo arm at a relatively high rate
despite well-controlled hyperglycemia, hyperlipidemia, and
blood pressure and that the reduction in CVD events with
bromocriptine-QR intervention was evident within the short
duration of this study in such a population of T2DM subjects.
Similarly, in this regard, it should be noted that the incidence
rate for the prespecified CVD endpoint among subjects in
the CST with baseline HbA1c >7.0% was 16/830 (1.9%) and
12/400 (3.0%) in the bromocriptine-QR and placebo arms,
respectively, comprising approximately half of the total events
in the original CST and yielding a hazard ratio of 0.74
(CI: 0.35–1.56) for this subset (HbA1c >7.0%). Although this
reduction in CVD events in this subset was not statistically
significant likely due to the small 𝑁 number, these findings
suggest an operative impact of this therapy in CVD risk
reduction across the continuum of glycemic control status.
CVD is the leading cause of death in T2DM subjects and
yet there are currently no antidiabetes medications available
with proven cardioprotective benefits. Consequently, the
CVD outcome findings described herein along with those
from other bromocriptine-QR intervention studies of T2DM
subjects [24, 25] suggest that bromocriptine-QR should be
considered for further investigation in larger, longer term
studies to establish or not the validity of its potential use early
in the course of T2DM as an cardioprotective agent.
5. Conclusion
In conclusion, the findings of this study support that
bromocriptine-QR therapy among T2DM subjects in good
glycemic control (HbA1c ≤7.0) reduced progression of dys-
glycemia and reduces CVD event rate within one year of
therapy. ReducingCVD remains amajor unmetmedical need
in T2DM. While reducing hyperglycemia may contribute
to such an outcome, the overall effects are modest. Other
major vascular risk factors such as vascular sympathetic
tone and endothelial dysfunction are present early in T2DM
disease progression (e.g., obesity/prediabetes) and represent
important therapeutic targets for CVD event rate reduction
even in subjects with good glycemic and metabolic con-
trol. Bromocriptine-QR is a sympatholytic dopamine D2
receptor agonist that appears to reduce these vascular risk
factors via the neuroendocrine axis and reduce progression
of CVD in T2DM even in the setting of good glycemic
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control. The present findings suggest that further larger,
longer term studies to assess the value of early intervention
with bromocriptine-QR during the chronology of T2DM to
provide unique long-term cardiovascular health benefits are
warranted.
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